1. Home
  2. KNSA vs CMPR Comparison

KNSA vs CMPR Comparison

Compare KNSA & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • CMPR
  • Stock Information
  • Founded
  • KNSA 2015
  • CMPR 1994
  • Country
  • KNSA United Kingdom
  • CMPR Ireland
  • Employees
  • KNSA N/A
  • CMPR N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • CMPR Publishing
  • Sector
  • KNSA Health Care
  • CMPR Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • CMPR Nasdaq
  • Market Cap
  • KNSA 1.7B
  • CMPR 2.1B
  • IPO Year
  • KNSA 2018
  • CMPR N/A
  • Fundamental
  • Price
  • KNSA $26.79
  • CMPR $76.92
  • Analyst Decision
  • KNSA Strong Buy
  • CMPR Strong Buy
  • Analyst Count
  • KNSA 5
  • CMPR 2
  • Target Price
  • KNSA $33.60
  • CMPR $119.50
  • AVG Volume (30 Days)
  • KNSA 283.3K
  • CMPR 120.9K
  • Earning Date
  • KNSA 10-29-2024
  • CMPR 10-30-2024
  • Dividend Yield
  • KNSA N/A
  • CMPR N/A
  • EPS Growth
  • KNSA N/A
  • CMPR N/A
  • EPS
  • KNSA N/A
  • CMPR 6.43
  • Revenue
  • KNSA $338,930,000.00
  • CMPR $3,291,856,000.00
  • Revenue This Year
  • KNSA $58.95
  • CMPR $7.63
  • Revenue Next Year
  • KNSA $36.22
  • CMPR $5.28
  • P/E Ratio
  • KNSA N/A
  • CMPR $11.96
  • Revenue Growth
  • KNSA 20.69
  • CMPR 6.89
  • 52 Week Low
  • KNSA $14.12
  • CMPR $57.01
  • 52 Week High
  • KNSA $27.92
  • CMPR $104.92
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 58.67
  • CMPR 36.06
  • Support Level
  • KNSA $23.33
  • CMPR $76.79
  • Resistance Level
  • KNSA $27.35
  • CMPR $82.63
  • Average True Range (ATR)
  • KNSA 0.89
  • CMPR 2.10
  • MACD
  • KNSA 0.15
  • CMPR -0.05
  • Stochastic Oscillator
  • KNSA 86.07
  • CMPR 2.23

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About CMPR Cimpress plc (Ireland)

Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.

Share on Social Networks: